π Health Issues (HCR)
Federal lobbying activity for the health issues issue area
AI Overview
Health Issues (HCR) has attracted $2.7B in lobbying spending across 100.9K filings. This is one of the most heavily lobbied issue areas in federal policy.
Spending by Year
Top Clients
| # | Client | Spending |
|---|---|---|
| 1 | HR Policy Association | $20.0M |
| 2 | Pharmaceutical Research and Manufacturers of America | $17.7M |
| 3 | Gilead Sciences, INC. | $13.1M |
| 4 | Pharmaceutical Research and Manufacturers of America (PHRMA) | $12.5M |
| 5 | PHRMA | $12.4M |
| 6 | Blue Cross Blue Shield Association | $10.0M |
| 7 | Johnson & Johnson Services, INC. | $9.1M |
| 8 | Cigna Corporation | $8.6M |
| 9 | Biotechnology Innovation Organization | $8.2M |
| 10 | Illumina, INC. | $7.9M |
| 11 | Genentech, INC. | $7.8M |
| 12 | Pharmaceutical Research & Manufacturers of America INC | $7.7M |
| 13 | Centene Corporation | $7.6M |
| 14 | Abbott Laboratories | $7.6M |
| 15 | Altria Client Services LLC | $7.4M |
| 16 | Unitedhealth Group, INC. | $7.2M |
| 17 | Alkermes, INC. | $6.9M |
| 18 | Air Evac Lifeteam | $6.8M |
| 19 | Novartis | $6.7M |
| 20 | Pfizer INC. | $6.7M |
Top Lobbying Firms
| # | Firm | Revenue |
|---|---|---|
| 1 | Tarplin, Downs & Young, LLC | $102.7M |
| 2 | BGR Government Affairs | $80.5M |
| 3 | Akin Gump Strauss Hauer & Feld | $61.6M |
| 4 | Mehlman Consulting, INC. | $56.5M |
| 5 | Forbes-tate | $55.9M |
| 6 | Alston & Bird LLP | $52.4M |
| 7 | Brownstein Hyatt Farber Schreck, LLP | $51.4M |
| 8 | Capitol Counsel LLC | $49.8M |
| 9 | Tiber Creek Group | $48.5M |
| 10 | Thorn Run Partners | $44.3M |
| 11 | Cornerstone Government Affairs, INC. | $42.4M |
| 12 | Invariant LLC | $37.2M |
| 13 | Van Scoyoc Associates | $36.6M |
| 14 | Williams and Jensen, PLLC | $35.3M |
| 15 | Avenue Solutions | $33.9M |
| 16 | Todd Strategy Group | $33.0M |
| 17 | Holland & Knight LLP | $31.3M |
| 18 | The Nickles Group, LLC | $28.9M |
| 19 | Farragut Partners LLP | $26.6M |
| 20 | Jeffrey J. Kimbell & Associates, INC. | $25.2M |
Sample Lobbying Descriptions
β’monitor for tax issues affecting real estate investment trusts general health care policy affecting hospitals and physician practices
β’allowing growth for hospitals with physician ownership
β’drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D
β’Controlled Substance act improvements. Opioid overdose death reduction. Alprazolam rescheduling.
β’Funding opportunities for first responder products
β’Matters related to healthcare, hospital ratings, and funding opportunities.
β’Help in the reduction of opioid use and related addiction.
β’Implementation of Public Law 115-80
β’Development of government-private partnerships to advance Alzheimer's therapies.
β’Issues surrounding Medicare Dependent Hospitals Preserving Medicare reimbursement rates for rural public hospitals serving a disproportionate Medicare/Medcaid patient mix.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.